MedTrace Logo

Prevention of CHOP-induced Chronic Cardiotoxicity

NCT00162955 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2012-05-08

No results posted yet for this study

Summary

The purpose of this study is to assess the protective effect of Valsartan on chronic cardiotoxicity induced by CHOP.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

Valsartan

Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.

Sponsors & Collaborators

  • Osaka City University

    lead OTHER

Principal Investigators

  • Masayuki Hino, MD, PhD · Graduate School of Medicine, Osaka City University

  • Hirohisa Nakamae, MD, PhD · Graduate School of Medicine, Osaka City University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00162955 on ClinicalTrials.gov